KYMR

🏥 Healthcare

Kymera Therapeutics, Inc.

Conservative #1139Aggressive #599Moderate RiskLow 4F↑ 33pt

Market Cap

$6.9B

P/E Ratio

N/A

Rev Growth

-40.1%

Sector avg: 161.5%

Earnings Growth

-52.3%

Profit Margin

-674.8%

Sector avg: -3292.7%

Debt/Equity

0.09

Why This Score

KYMR scores 28.8 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.

Strengths

Minimal leverage (D/E 0.09) provides financial flexibility and downside protection.

Risk Factors

Momentum reversion risk: Extreme momentum (163%) increases mean-reversion probability. 3-point penalty applied.
Signal divergence: Fundamental and ML signals disagree by a significant margin, reducing confidence.
Above-average volatility (18.5%) may not suit conservative risk tolerance.

Net penalties of -24.1 points significantly impact the ranking. Without these adjustments, KYMR would rank considerably higher.

Score Breakdown

Overall Score28.8

Fundamental Score38.2

ML Score79.0

Score by Horizon

3 Month

7.0

6 Month

7.9

Primary

1 Year

8.3

Quality Assessment

Earnings Grade

Weak fundamentals or significant quality concerns

Speculative Classification

Speculative growth — negative margins and ROE with momentum-driven price action. High risk of mean reversion.

Anomalous margin data — extreme values suggest one-time events or accounting irregularities.

Conservative score reduced by 7 points.

Position Sizing

Suggested Allocation

4.3%

Confidence

high

Score Composition Waterfall

How each component affects the final score

Backtested Scoring Levers (IC-calibrated from 30y ElasticNet)

Weinstein (12.1%)

100

Advancing

Sentiment (2.5%)

Positive

Analyst (6.4%)

Favorable

Tradability (post-hoc)

Grade A

Base

36.4

SHAP

+1.4

Factors

-0.7

Conviction

-4.4

Divergence

-3.9

Final

28.8

Positive adjustment

Negative adjustment

Base blend

Final score

Signal SegmentsComputed from ML features

Fundamental (Valuation, Quality, Growth)33.0

Technical (Momentum, Weinstein, Volatility)87.0

External (Sentiment, Analyst, Macro)88.0

Scores below 50 indicate weakness in that segment relative to the universe.

Data Quality

Score

Features

Confidence

Feature Coverage89%

Growth Estimates

Short-term

-30.0% to -18.0%

Medium-term

-40.6% to -24.6%

Long-term

-51.8% to -29.6%

ML Model Core Features100 trained inputs → ML Score: 79

These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.

Analyst Intelligence

Consensus Score72.1/100

Target Upside+35.0%

Coverage26 analysts

Market Sentiment

Sentiment Score79.5/100

News Volume1 articles

Technical Stage

Weinstein Stage2 — Advancing

12M Momentum+1.6%

6M Momentum+1.0%

Volatility+0.2%

Momentum & Technical

Momentum Acceleration+62.8%

Momentum ConsistencyModerate (0.61)

Relative Strength vs Sector+138.2%

Trend Strength (ADX Proxy)Strong (5.0)

Momentum Quality+1.407

Momentum BreadthBroad ✓

Macro Regime

Bull RegimeYes

High Vol RegimeNo

S&P 500 Return+25.0%

Yield Curve-0.1bp

Sector-Relative AnalysisIn-model features

Value Trap Signal

16%

Moderate — watch growth

Sector RevGr Rank

Revenue growth vs Healthcare peers

Sector PE Rank

P40

Valuation vs Healthcare peers

Sector FCF Rank

P42

Free cash flow vs Healthcare peers

Growth Deviation

-0.0σ

Z-score vs sector median

Stagnation Flag

Not flagged

Analysis Signals

Scoring Factors

Fundamental score of 56 relative to sector peers56/100

Machine learning model ranks this stock at the 23th percentileP23

ML model weight reduced to 9% due to macro conditions: market in extended rally phase; yield curve inverted (recession indicator); late-cycle economic indicators detected9% ML weight

SHAP feature alignment: +1.4pt (features align with model priorities)—

Blend: 91% fund (56.1) + 9% ML (22.4) + SHAP(+1.4) = 54.5—

Factor quality: -0.7pt (multi-factor composite)—

Risk assessment: moderate. Annualized volatility 18.5%. Max drawdown 14% (-2.2 pts)Moderate

Momentum mean-reversion: -4.1pt (163% 12m momentum)—

Market cap adjustment: +0.5 points ($6.9B market cap)+0.5 pts

Conviction penalty: -4.4pt (conviction=4)—

Divergence penalty: -3.5pt (fund 33pt higher)—

Risk Factors

Earnings quality grade F: assessed. Score adjusted by -30 pointsGrade F

Quality concern: Non-operating gain: net margin (-674.8%) exceeds operating margin (-759.7%) by 85pp — likely one-time item; High accrual ratio (22.8%) — earnings quality concernFlag

Sector Peer Comparison(Healthcare — Rank #231 of 344 stocks)

Stock	Score	P/E	Rev Growth	Margin	Mkt Cap
KYMRKymera Therapeutics, Inc.	28.8	N/A	-40.1%	-674.8%	$6.9B
INCYIncyte Corporation	89.6	15.8	21.2%	25.0%	$20.1B
GMABGenmab A/S	85.5	13.1	22.8%	36.4%	$18.5B
CPRXCatalyst Pharmaceuticals, Inc.	82.2	13.7	23.5%	37.6%	$3.0B
VRTXVertex Pharmaceuticals Incorpor	78.0	32.1	8.9%	32.9%	$126.0B
ASNDAscendis Pharma A/S	75.7	16.6	98.0%	-31.7%	$13.3B
NBIXNeurocrine Biosciences, Inc.	74.7	26.5	21.4%	16.7%	$12.5B
ALKSAlkermes plc	74.6	16.5	-6.4%	23.9%	$5.5B
AMGNAmgen Inc.	73.8	26.0	10.0%	21.0%	$199.0B
ARGXargenx SE	73.6	35.1	78.6%	38.0%	$50.9B
HOLXHologic, Inc.	73.3	31.1	1.7%	13.8%	$16.8B
REGNRegeneron Pharmaceuticals, Inc.	72.7	19.4	1.0%	31.4%	$84.9B
ISRGIntuitive Surgical, Inc.	72.3	61.7	20.5%	28.4%	$172.5B
EXELExelixis, Inc.	71.9	15.1	7.0%	33.7%	$11.7B
KRYSKrystal Biotech, Inc.	71.0	41.4	473.0%	30.7%	$8.0B
HALOHalozyme Therapeutics, Inc.	70.2	16.8	22.4%	43.7%	$9.3B
Sector Average	37.1	252.3	161.5%	-3292.7%	—

Market Sentimentvia FMP

No analyst sentiment data available for KYMR.

Why This Stock

Healthcare

Tradability FilterGrade A — 88/100Score impact: -37.1pt

Volume

100

990K avg/day

Dollar Vol

100

$88M/day

Float

0K shares

Mkt Cap

$6.9B

Range

100

430% spread

Composite Liquidity Score88/100

FDCBA

Multi-Year Range Analysis

Sideways: 0/100

Year	Low	High	Range	Status
2021	$29.93	$69.12	79.1%	Wide
2022	$13.15	$65.44	133.1%	Wide
2023	$9.60	$39.85	122.3%	Wide
2024	$22.35	$53.27	81.8%	Wide
2025	$19.45	$103.00	136.5%	Wide

3-Year Range

165.9%

Narrow Years

0 / 5

Sideways Penalty

None

Growth Projection Adjustment

0.3x dampening

severe revenue decline

Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.

Free Float

0.0%

Outstanding Shares

Bid-Ask Spread

430.0%

Institutional Tradable

Yes

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.